These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21484981)

  • 41. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
    Alkemade GM; Hilbrands R; Vandemeulebroucke E; Pipeleers D; Waldmann H; Mathieu C; Keymeulen B; Roep BO
    Diabetes Metab Res Rev; 2011 Nov; 27(8):925-7. PubMed ID: 22069286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice.
    Chen G; Han G; Wang J; Wang R; Xu R; Shen B; Qian J; Li Y
    Am J Pathol; 2008 Apr; 172(4):972-9. PubMed ID: 18349126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced tumor necrosis factor in anti-CD3 antibody stimulated diabetic NOD mice: modulation by PGE1 and dietary lipid.
    Barel D; Brennan DC; Jevnikar AM; Bastos M; Strom TB; Kelley VR
    Autoimmunity; 1992; 13(2):141-9. PubMed ID: 1467435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thymus-dependent monoclonal antibody-induced protection from transferred diabetes.
    Parish NM; Bowie L; Zusman Harach S; Phillips JM; Cooke A
    Eur J Immunol; 1998 Dec; 28(12):4362-73. PubMed ID: 9862373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.
    Sarikonda G; Sachithanantham S; Miller JF; Pagni PP; Coppieters KT; von Herrath M
    J Autoimmun; 2015 May; 59():61-6. PubMed ID: 25772283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel T-cell inhibiting peptides delay the onset of Type 1 diabetes in non-obese diabetic mice.
    Wong MS; Tso A; Ali M; Hawthorne WJ; Manolios N
    Diabetes Metab; 2014 Jun; 40(3):229-34. PubMed ID: 24630734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.
    Kuhn C; You S; Valette F; Hale G; van Endert P; Bach JF; Waldmann H; Chatenoud L
    Sci Transl Med; 2011 Feb; 3(68):68ra10. PubMed ID: 21289272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prevent and cure insulin-dependent diabetes].
    Bach JF
    Pathol Biol (Paris); 2003 Apr; 51(3):151-5. PubMed ID: 12781796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In utero undernutrition reduces diabetes incidence in non-obese diabetic mice.
    Oge A; Isganaitis E; Jimenez-Chillaron J; Reamer C; Faucette R; Barry K; Przybyla R; Patti ME
    Diabetologia; 2007 May; 50(5):1099-108. PubMed ID: 17370059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.
    Ochi H; Abraham M; Ishikawa H; Frenkel D; Yang K; Basso A; Wu H; Chen ML; Gandhi R; Miller A; Maron R; Weiner HL
    J Neurol Sci; 2008 Nov; 274(1-2):9-12. PubMed ID: 18804221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.
    Perl S; Perlman J; Weitzel RP; Phang O; Hsieh MM; Tisdale J
    PLoS One; 2013; 8(6):e67189. PubMed ID: 23826229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
    Valle A; Jofra T; Stabilini A; Atkinson M; Roncarolo MG; Battaglia M
    Diabetes; 2009 Apr; 58(4):875-81. PubMed ID: 19151201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis.
    Mfarrej B; Keir M; Dada S; Trikudanathan S; Sayegh MH; Sharpe AH; Guleria I
    Clin Immunol; 2011 Jul; 140(1):47-53. PubMed ID: 21498129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral
    Cobb J; Rawson J; Gonzalez N; Hensel M; Kandeel F; Husseiny MI
    Front Immunol; 2021; 12():667897. PubMed ID: 34108968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulatory and renal consequences of pregnancy in diabetic NOD mice.
    Burke SD; Barrette VF; David S; Khankin EV; Adams MA; Croy BA
    Placenta; 2011 Dec; 32(12):949-55. PubMed ID: 22014504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgG2a antibodies non-specifically delay the onset of diabetes in NOD mice.
    Todd I; Davenport C; Topping JH; Wood PJ
    Autoimmunity; 1998; 27(4):209-11. PubMed ID: 9623498
    [No Abstract]   [Full Text] [Related]  

  • 57. The immunomodulation to diabetes control: New proposals for the reversion of this disease.
    Mâncio RD; Minatel E; de Almeida Cardoso M; Ali Khan B; José Caldeira E
    Diabetes Metab Syndr; 2015; 9(4):210-2. PubMed ID: 26321040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of type 1 diabetes: where do we start?
    Pozzilli P; Adorini L
    J Endocrinol Invest; 2003 Apr; 26(4):292-3. PubMed ID: 12841534
    [No Abstract]   [Full Text] [Related]  

  • 59. Prevention of diabetes mellitus in the non-obese diabetic mouse strain with monoclonal antibodies against the CD45RB molecule.
    Abu-Hadid MM; Lazarovits AI; Madrenas J
    Autoimmunity; 2000; 32(1):73-6. PubMed ID: 10958178
    [No Abstract]   [Full Text] [Related]  

  • 60. Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review.
    Li W; Wang H; Chen B; Zhao S; Zhang X; Jia K; Deng J; He Y; Zhou C
    Transl Lung Cancer Res; 2020 Apr; 9(2):379-388. PubMed ID: 32420079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.